Indoco Remedies Limited (INDOCO.BO)
INR 235.05
(0.45%)
INR 235.05
(0.45%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.47 Billion INR | 101.18% |
| 2022 | 3.21 Billion INR | 34.58% |
| 2021 | 2.39 Billion INR | -7.04% |
| 2020 | 2.57 Billion INR | 5.01% |
| 2019 | 2.45 Billion INR | -11.6% |
| 2018 | 2.77 Billion INR | 1.23% |
| 2017 | 2.73 Billion INR | 24.46% |
| 2016 | 2.2 Billion INR | 91.8% |
| 2015 | 1.14 Billion INR | 47.85% |
| 2014 | 775.88 Million INR | 32.93% |
| 2013 | 583.67 Million INR | -25.39% |
| 2012 | 782.31 Million INR | -24.55% |
| 2011 | 1.03 Billion INR | 95.55% |
| 2010 | 530.22 Million INR | 86.08% |
| 2009 | 284.93 Million INR | 6.66% |
| 2008 | 267.15 Million INR | 0.0% |
| 2006 | 201.27 Million INR | 133.23% |
| 2005 | 86.29 Million INR | -59.24% |
| 2004 | 211.7 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 3.62 Billion INR | 2485.46% |
| 2024 Q1 | 315.7 Million INR | -95.13% |
| 2023 FY | 6.47 Billion INR | 101.18% |
| 2023 Q1 | 143.4 Million INR | -95.55% |
| 2023 Q2 | 4.35 Billion INR | 2933.54% |
| 2023 Q3 | 682.5 Million INR | -84.31% |
| 2023 Q4 | 6.47 Billion INR | 848.91% |
| 2022 FY | 3.21 Billion INR | 34.58% |
| 2022 Q1 | 197.8 Million INR | -91.73% |
| 2022 Q2 | 2.8 Billion INR | 1316.99% |
| 2022 Q4 | 3.21 Billion INR | 677.96% |
| 2022 Q3 | 413.8 Million INR | -85.24% |
| 2021 FY | 2.39 Billion INR | -7.04% |
| 2021 Q4 | 2.39 Billion INR | 873.15% |
| 2021 Q3 | 245.8 Million INR | -90.35% |
| 2021 Q2 | 2.54 Billion INR | 1675.59% |
| 2021 Q1 | 143.4 Million INR | -94.43% |
| 2020 Q3 | 432.4 Million INR | -77.37% |
| 2020 Q4 | 2.57 Billion INR | 495.1% |
| 2020 FY | 2.57 Billion INR | 5.01% |
| 2020 Q1 | 416.5 Million INR | -83.0% |
| 2020 Q2 | 1.91 Billion INR | 358.82% |
| 2019 Q2 | 1.82 Billion INR | 779.65% |
| 2019 Q1 | 207.96 Million INR | -92.5% |
| 2019 Q4 | 2.45 Billion INR | 463.47% |
| 2019 Q3 | 434.9 Million INR | -76.23% |
| 2019 FY | 2.45 Billion INR | -11.6% |
| 2018 FY | 2.77 Billion INR | 1.23% |
| 2018 Q4 | 2.77 Billion INR | 0.0% |
| 2018 Q1 | 85.81 Million INR | 0.0% |
| 2017 FY | 2.73 Billion INR | 24.46% |
| 2016 FY | 2.2 Billion INR | 91.8% |
| 2015 FY | 1.14 Billion INR | 47.85% |
| 2014 FY | 775.88 Million INR | 32.93% |
| 2013 FY | 583.67 Million INR | -25.39% |
| 2012 Q4 | 1.06 Billion INR | 0.0% |
| 2012 FY | 782.31 Million INR | -24.55% |
| 2011 FY | 1.03 Billion INR | 95.55% |
| 2010 FY | 530.22 Million INR | 86.08% |
| 2009 FY | 284.93 Million INR | 6.66% |
| 2008 FY | 267.15 Million INR | 0.0% |
| 2006 FY | 201.27 Million INR | 133.23% |
| 2005 FY | 86.29 Million INR | -59.24% |
| 2004 FY | 211.7 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -67.524% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -75.353% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 327.825% |
| Granules India Limited | 9.28 Billion INR | 30.263% |
| Achyut Healthcare Limited | -3.74 Million INR | 172985.745% |
| Ajanta Pharma Limited | -954.9 Million INR | 778.218% |
| Alkem Laboratories Limited | -1.6 Billion INR | 502.405% |
| Alpa Laboratories Limited | 35.36 Million INR | -18213.774% |
| Brooks Laboratories Limited | 49.48 Million INR | -12987.4% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 229.205% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -96.314% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 659.386% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 49.847% |
| Eris Lifesciences Limited | 13.8 Billion INR | 53.092% |
| FDC Limited | -57.75 Million INR | 11313.984% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 251.13% |
| Gufic Biosciences Limited | 3.19 Billion INR | -102.744% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 255.941% |
| Ipca Laboratories Limited | 11.41 Billion INR | 43.266% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 565.944% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -235.052% |
| Lasa Supergenerics Limited | 205.79 Million INR | -3046.905% |
| Laurus Labs Limited | 24.38 Billion INR | 73.441% |
| Lupin Limited | 17.19 Billion INR | 62.33% |
| Mankind Pharma Limited | -9.9 Billion INR | 165.364% |
| Medicamen Biotech Limited | 160.31 Million INR | -3939.709% |
| Medico Remedies Limited | 78.67 Million INR | -8131.503% |
| Megasoft Limited | 1.28 Billion INR | -403.776% |
| NATCO Pharma Limited | -5.81 Billion INR | 211.334% |
| Piramal Pharma Limited | 42.27 Billion INR | 84.681% |
| RPG Life Sciences Limited | -364.7 Million INR | 1875.788% |
| Sigachi Industries Limited | 859.94 Million INR | -653.103% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 108.937% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -4367.153% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -13914.629% |
| Unichem Laboratories Limited | 931.91 Million INR | -594.945% |
| Wanbury Limited | 1.1 Billion INR | -485.627% |
| Windlas Biotech Limited | -273.04 Million INR | 2471.924% |
| ZIM Laboratories Limited | 983.6 Million INR | -558.426% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -65.55% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 787.651% |
| Divi's Laboratories Limited | -39.77 Billion INR | 116.284% |
| Hester Biosciences Limited | 2.29 Billion INR | -182.717% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 375.822% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 2703.098% |
| Bal Pharma Limited | 1.26 Billion INR | -412.544% |
| Strides Pharma Science Limited | 23.25 Billion INR | 72.153% |
| Venus Remedies Limited | -267.7 Million INR | 2519.238% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -147.954% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -5.181% |
| Shilpa Medicare Limited | 9.06 Billion INR | 28.593% |
| Aarti Drugs Limited | 5.54 Billion INR | -16.724% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 688.06% |
| Suven Life Sciences Limited | -1.63 Billion INR | 496.662% |
| Ind-Swift Limited | 9.5 Billion INR | 31.89% |
| Valiant Laboratories Limited | -295.03 Million INR | 2295.118% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -129.558% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 35.424% |
| Themis Medicare Limited | 764.96 Million INR | -746.617% |
| Hikal Limited | 7.96 Billion INR | 18.711% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 79.653% |
| Sequent Scientific Limited | 4.17 Billion INR | -54.986% |
| Novartis India Limited | -5.89 Billion INR | 209.934% |
| Wockhardt Limited | 18.27 Billion INR | 64.552% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 76.077% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 35209.509% |
| Neuland Laboratories Limited | -214.05 Million INR | 3125.488% |
| Morepen Laboratories Limited | -231.17 Million INR | 2901.483% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -5295.163% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -563.684% |